Literature DB >> 24862319

The potential and advances in RNAi therapy: chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers.

Min Kyung Joo1, Ji Young Yhee1, Sun Hwa Kim2, Kwangmeyung Kim3.   

Abstract

Small interfering RNA (siRNA) has attracted great attention as a potential new drug due to its highly sequence-specific gene silencing ability and generality in therapeutic target. However, the medical applications of siRNA have been severely hindered by the lack of an optimal systemic delivery methodology. This poor delivery performance of siRNA is mainly caused by its inherent physicochemical properties including short and stiff structure, low charge density and vulnerability to nuclease cleavage. Thus, the successful development of efficient systemic delivery platform for siRNA is a fundamental requirement necessary to bring siRNA-based drugs to the market. Herein, we describe some siRNA delivery methods based on the chemical and structural modifications of delivery materials and siRNA itself to carry siRNA therapeutics safely to the targeted place without adverse effects. This review particularly explains the latest progress of chemically and structurally modified siRNA polymer (poly-siRNA)-based delivery systems. The stable and compact siRNA polyplexes, which are formed by poly-siRNA and different types of biocompatible materials, can enhance serum stability and target delivery efficiency in vitro and in vivo. In addition, this review provides specific information on poly-siRNA delivery systems from basics to therapeutic applications in different animal disease models.
Copyright © 2014 Elsevier B.V. All rights reserved.

Keywords:  Chemical and structural modifications; Gene delivery; Polymerized siRNA; RNA interference

Mesh:

Substances:

Year:  2014        PMID: 24862319     DOI: 10.1016/j.jconrel.2014.05.030

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  10 in total

1.  CD73 downregulation by EGFR-targeted liposomal CD73 siRNA potentiates antitumor effect of liposomal doxorubicin in 4T1 tumor-bearing mice.

Authors:  Anvar Soleimani; Farshad Mirzavi; Sara Nikoofal-Sahlabadi; Amin Reza Nikpoor; Bita Taghizadeh; Mehdi Barati; Mohammad Soukhtanloo; Mahmoud Reza Jaafari
Journal:  Sci Rep       Date:  2022-06-21       Impact factor: 4.996

Review 2.  Cell-penetrating peptides and their analogues as novel nanocarriers for drug delivery.

Authors:  Samira Jafari; Solmaz Maleki Dizaj; Khosro Adibkia
Journal:  Bioimpacts       Date:  2015-04-22

3.  Evaluating side effects of nanoparticle-mediated siRNA delivery to mesenchymal stem cells using next generation sequencing and enrichment analysis.

Authors:  Dominic W Malcolm; Janet E Sorrells; Daniel Van Twisk; Juilee Thakar; Danielle S W Benoit
Journal:  Bioeng Transl Med       Date:  2016-10-24

4.  FGFR3 silencing by siRNA inhibits invasion of A549 cells.

Authors:  Yuhua Li; Xiguang Liu; Hongjun Zhang; Tao Jiang; Wenjing Xiao; Shufen Zhao; Xiaoyun Yu; Fanjie Han
Journal:  Oncol Lett       Date:  2016-10-18       Impact factor: 2.967

5.  Cell-Penetrating Peptide-Modified Graphene Oxide Nanoparticles Loaded with Rictor siRNA for the Treatment of Triple-Negative Breast Cancer.

Authors:  Yun-Yun Yang; Wei Zhang; Hui Liu; Jun-Jie Jiang; Wen-Jie Wang; Zheng-Yan Jia
Journal:  Drug Des Devel Ther       Date:  2021-12-10       Impact factor: 4.162

6.  Cationic star-shaped polymer as an siRNA carrier for reducing MMP-9 expression in skin fibroblast cells and promoting wound healing in diabetic rats.

Authors:  Na Li; Heng-Cong Luo; Chuan Yang; Jun-Jie Deng; Meng Ren; Xiao-Ying Xie; Diao-Zhu Lin; Li Yan; Li-Ming Zhang
Journal:  Int J Nanomedicine       Date:  2014-07-15

7.  siRNAmod: A database of experimentally validated chemically modified siRNAs.

Authors:  Showkat Ahmad Dar; Anamika Thakur; Abid Qureshi; Manoj Kumar
Journal:  Sci Rep       Date:  2016-01-28       Impact factor: 4.379

8.  Intron-specific shRNA-mediated downregulation of survivin and promotion of apoptosis in HeLa cells.

Authors:  Yue-Li Wang; Xin Shao; Fa Wang; Liang Zeng; Liang Hu; Shi-Quan Cui; Gan Hou; Di-Nan Huang
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967

9.  In vivo therapeutic efficacy of TNFα silencing by folate-PEG-chitosan-DEAE/siRNA nanoparticles in arthritic mice.

Authors:  Qin Shi; Elsa-Patricia Rondon-Cavanzo; Isadora Pfeifer Dalla Picola; Marcio José Tiera; Xiaoling Zhang; Kerong Dai; Houda Abir Benabdoune; Mohamed Benderdour; Julio Cesar Fernandes
Journal:  Int J Nanomedicine       Date:  2018-01-12

10.  Nonconserved miR-608 suppresses prostate cancer progression through RAC2/PAK4/LIMK1 and BCL2L1/caspase-3 pathways by targeting the 3'-UTRs of RAC2/BCL2L1 and the coding region of PAK4.

Authors:  Xu Zhang; Jiajie Fang; Shiming Chen; Weiyu Wang; Shuai Meng; Ben Liu
Journal:  Cancer Med       Date:  2019-08-07       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.